The group says its prices in the third quarter were 2% lower on a global basis, offset by 4% volume growth. US drug firms are to increase prices next year after an undertaking to delay increases expired. Merck is to raise the cost of two drugs, including immuno-oncology treatment Keytruda in the new year , while Keytruda has said next year will be "business as normal" with regard to pricing, with other companies expected to follow their lead. Global prices dipped by 2% in Q3 and big pharma will be seeking to make up for any lost growth. Congressional hearings on drug costs are due the new year , which may affect companies' ability to raise prices.
US drug firms are to increase prices next year after an undertaking to delay increases expired. Merck is to raise the cost of two drugs, including immuno-oncology treatment Keytruda in the new year , while Keytruda has said next year will be "business as normal" with regard to pricing, with other companies expected to follow their lead. Global prices dipped by 2% in Q3 and big pharma will be seeking to make up for any lost growth. Congressional hearings on drug costs are due the new year , which may affect companies' ability to raise prices.